diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md
index 075f700e..3a147686 100644
--- a/pages/InCORNTD 2025___Application.md	
+++ b/pages/InCORNTD 2025___Application.md	
@@ -1,6 +1,6 @@
 # [[2024/10/30]]
 	- **Título**: Fixed dose albenzadole/ivermectin coformulation, an innovative tool to help countries achieve their NTD control goals in a post-donation era
 	- **Description**: The fixed-dose coformulation of albendazole and ivermectin is the result of 10+ years of innovations carried out by African and European organizations working through public-private partnerships. 
-	  This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial and is currently being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA.
-	  The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing better efficacy against more species of helminths.
+	  This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial and is currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration.
+	  The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control
 -
\ No newline at end of file